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Available online 5 August 2016Homozygous loss-of-function mutations in the gene coding for the homeobox transcription factor PDX1 leads to
pancreatic agenesis, whereas certain heterozygous point mutations are associated with Maturity-Onset Diabetes
of the Young 4 (MODY4) and Type 2 Diabetes Mellitus (T2DM). To understand the pathomechanism of MODY4
and T2DM, we have generated iPSCs from a woman with a P33T heterozygous mutation in the transactivation
domain of PDX1. The resulting PDX1 P33T iPSCs generated by episomal reprogramming are integration-free,
have a normal karyotype and are pluripotent in vitro and in vivo. Taken together, this iPSC line will be useful to
study diabetes pathomechanisms.
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The Tübingen Family Study for T2DM (TÜF study, N = 2500) was
screened for known rare mutations in the MODY4 gene PDX1. By mass
spectrometry-based genotyping, one heterozygous PDX1 P33T carrier
could be identiﬁed and recruited for full-thickness skin biopsy. From
the biopsymaterial, the epidermal layer was separated from the dermis
by dispase digestion and ﬁbroblasts were isolated from the dermis by
trypsin digestion using an established protocol (see Materials and
methods section). The PDX1 P33T ﬁbroblasts were expanded using
commercially available growth media and deep-frozen in liquid nitro-
gen. From this collection of dermal ﬁbroblasts, samples were tested
for the presence of viruses pathogenic to humans (HBV, HCV, HIV) as
well as for the presence of mycoplasma. All cultures were found to be
negative for all of these potential contaminants. PDX1 P33T primary ﬁ-
broblasts were reprogrammed into iPSCs using nucleofection with
three episomal plasmids encoding human OCT4, SOX2, NANOG, LIN28,
KLF4, and L-MYC (Fig. 1B). The reprogramming protocol (transfection,
reprogramming and expansion) is shown in Fig. 1C. Three weeks after
transfection, many colonies with human embryonic stem cell (hESC)-article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Generation of PDX1 P33T iPSCs. (A) An overview of the PDX1 protein structure. (B) Scheme shows the reprogramming factors for the generation of the PDX1 P33T iPSC line. (C)
Reprogramming protocol of skin ﬁbroblasts into integration-free iPSCs using episomal vectors. (D) Normal karyotype (46, XX) of one PDX1 P33T iPSC clone. (E) Sequencing result
shows heterozygous CNA mutation in PDX1. (F) Semi-quantitative PCR conﬁrms that episomal vectors did not integrate into the genomic DNA of the selected PDX1 P33T iPSC clone.
H9 ESCs were used as a negative control, whereas transfected ﬁbroblasts at day 6 were used as positive controls.
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and frozen down as individual iPSC lines. The analysis of one of these
iPSC lines conﬁrmed that PDX1 P33T ﬁbroblasts were successfully
reprogrammed into iPSCs with a normal karyotype (Fig. 1D) and con-
taining the CNA mutation causing a P33T amino acid exchange in the
transactivation domain (Fig. 1A, E). Integration of the exogenous
transgenes in the genome of iPSCs was excluded by semi-quantitative
PCR (Fig. 1F). To conﬁrm that this iPSC line was pluripotent, we per-
formed immunoﬂuorescence staining for the pluripotency transcription
factors OCT4 and SOX2, as well as for the hESC surface markers SSEA-3,
SSEA-4 and TRA-1-81, which were all expressed in the PDX1 P33T iPSC
line (Fig. 2A). To further demonstrate pluripotency of the selected iPSC
line we injected 2 × 106 cells subcutaneously into NOD/SCID mice to
generate teratomas. The histological analysis of the induced teratomas
revealed that all tissues from all three germ layers were differentiated
conﬁrming pluripotency in this in vivo assay (Fig. 2B). Taken together,
we have successfully reprogrammed PDX1 P33T dermal ﬁbroblastsinto pluripotent iPSCs that can be used to study a point mutation in
the transactivation domain of PDX1 to study the development of
diabetes.
3. Materials and methods
3.1. Ethics statement
The study adhered to the Declaration of Helsinki. All participants
gave informed written consent, and the study protocols were approved
by the local ethics board (Ethics Committee of the Eberhard Karls Uni-
versity Tübingen).
3.2. Study participants
The ongoing TÜF study currently includes N3000 non-related individ-
uals at risk for type-2 diabetesmellitus (T2DM), i.e., healthy subjects with
Fig. 2. PDX1 P33T iPSCs are pluripotent and differentiate into all germ layers in vivo. (A) PDX1 P33T iPSCs display typical morphological ESC-like characteristics and uniformly express
several pluripotency markers. Scale bar indicates 50 μm. (B) Hematoxylin/eosin staining of tissue sections of teratomas generated from the PDX1 P33T iPSC clone. All germ layer-
derivatives are clearly detectable in vivo. Scale bar indicates 100 μm.
275X. Wang et al. / Stem Cell Research 17 (2016) 273–276a family history of T2DM, a bodymass index ≥27 kg/m2, impaired fasting
glycemia, and/or previous gestational diabetes (Stefan N, Machicao F,
Staiger H, Machann J, Schick F, Tschritter O, Spieth C, Weigert C, Fritsche
A, Stumvoll M, Häring HU. Polymorphisms in the gene encoding
adiponectin receptor 1 are associated with insulin resistance and high
liver fat. Diabetologia 2005;48:2282-2291). From all TÜF participants,
the medical history, smoking status, and alcohol consumption habits
were queried and documented. Furthermore, all participants underwent
physical examination, routine blood tests, bioelectric impedance mea-
surement, and 5-point oral glucose tolerance tests (OGTTs) with insulin
and glucose measurements. The current study population comprised
2500 individuals who spent DNA for genotyping, were not on any medi-
cation known to inﬂuence glucose tolerance, insulin sensitivity, or insulin
secretion, and who had complete OGTT data sets.
Using the mass spectrometry-based genotyping platform
MassARRAY from Sequenom (Hamburg, Germany) and the
manufacturer's iPLEX software, the 2500 subjects were screened for
known rare mutations in maturity onset of diabetes (MODY) genes
thatwere described in the literature to co-segregatewithMODYpheno-
types in families. We identiﬁed seven individuals with heterozygous
mutations in PDX1 (MODY4) (McKinnon andDocherty, 2001).We iden-
tiﬁed seven individuals with heterozygous mutations in PDX1
(MODY4). From these cases, one glucose-tolerant female PDX1
Pro33Thr (P33T) carrier (aged 40 years; BMI 23.0 kg/m2) could be re-
cruited for full-thickness skin biopsy.3.3. Skin biopsy, isolation and testing of dermal ﬁbroblasts
A full-thickness skin specimen was taken by punch biopsy from
the upper arm in the deltoid muscle region. After removal of adi-
pose tissue remnants and visible blood vessels, the sample was
digested overnight at 4 °C with 10 U/ml dispase II (Roche Diagnos-
tics, Mannheim, Germany) in 50 mM Hepes pH .4, 150 mM NaCl.
Thereafter, the digest was heated for 30 min at 37 °C under con-
tinuous shaking (1200 rpm). Using forceps, the dermis was sepa-
rated from the epidermal layer, and ﬁbroblasts were isolated
from the dermis by digestion with 0.2% collagenase CLS I
(Biochrom, Berlin, Germany) in DMEM, 10% BSA for 45 min at
37 °C under continuous shaking (1200 rpm). For puriﬁcation of
the ﬁbroblasts, the digest was ﬁltered through a 70 μm mesh
and centrifuged. The pelleted cells were resuspended, grown for
three days in DMEM, 10% FCS, and subsequently further expanded
in Medium 106 supplemented with low serum growth supplement
(Invitrogen, Thermo Fisher Scientiﬁc, Waltham, MA, USA). Sam-
ples of dermal ﬁbroblasts were tested for the presence of viruses
pathogenic to humans, i.e., HBV, HCV, and HIV, with Genesig
PCR-based detection kits from Primerdesign Ltd. (Chandler's
Ford, UK) and for the presence of mycoplasma with a PCR test
kit from PanReac AppliChem (Darmstadt, Germany) and, in paral-
lel, by DNA staining with DAPI. All cultures were found to be neg-
ative for the tested contaminants.
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Primary ﬁbroblasts frompatientwere reprogrammed into pluripotent
stem cells by using a non-integrating Episomal iPSC Reprogramming Kit
(Invitrogen, Cat. no. A14703). This kit contains mixture of three vectors
which has the oriP/EBNA-1 (Epstein-Barr unclear antigen-1) backbone
that delivers six reprogramming factors: OCT4, SOX2, NANOG, LIN28,
KLF4, and L-MYC (Yu et al., 2011). Human ﬁbroblasts at 75–90% conﬂuent
were transfected using the Amaxa 4D-Nucleofector transfection system
and a nucleofector kit for human dermal ﬁbroblast (Lonza, Cat. no.VPD-
1001), plated onto geltrex-coated culture dishes, incubated in supple-
mented ﬁbroblast medium. This medium contained knockout DMEM/F-
12 (Life Technologies), 10% FBS of ESC-qualiﬁed (Life Technologies), 1%
MEM non-essential amino acids (Life Technologies), 10 μM HA-100
(Santa Cruz) and 4 ng/ml bFGF (Life Technologies). At 24 h after transfec-
tion, the medium was exchanged with N2B27 medium supplemented
with 0.5 μM PD0325901 (Stemgent), 3 μM CHIR99021 (Stemgent),
0.5 μM A-83-01 (Stemgent), 10 μM HA-100 (Santa Cruz), 10 ng/ml hLIF
(Life Technologies) and 100 ng/ml bFGF. The basic N2B27 medium
containedDMEM/F12withHEPES (Life Technologies), 1×N2 supplement
(Life Technologies), 1× B27 supplement (Life Technologies), 1% MEM
non-essential amino acids, 1× Glutamax (Life Technologies) and 1× β-
Mercaptoethanol (Life Technologies). On day 15 after transfection, the
medium was exchanged with Essential 8 medium and monitored for
the emergence of iPSC colonies. Around 3weeks after transfection, undif-
ferentiated iPS colonies were picked and transferred onto fresh geltrex-
coated culture dishes for expansion.
3.5. iPSC characterization
DNA was extracted from iPSCs by using standard procedure. Markers
for the episomal backbone were ampliﬁed by semi-quantitative PCR to
exclude transgene integration. Primers are as follows: oriP forward:
TTCCACGAGGCTAGTGAACC. oriP reverse: TCGGGGGTGTTAGAGACAAC;
EBNA-1 forward: ATCGTCAAAGCTGCACACAG. EBNA-1 reverse:
CCCAGGAGTCCCAGTAGTCA. For karyotype analysis, we used the cells
growing in logarithmic phase. They were fed with fresh medium the
night before adding colcemid for 2 h. Cells were then trypsinized, treated
with hypotonic solution (0.075 m KCl) for 20 min and ﬁxed with
methanol:acetic acid (3:1). Metaphases were spread on microscope
slides, and chromosomes were classiﬁed according to the International
System forHumanCytogenicNomenclature using the standardGbanding
technique. At least, 20 metaphases were counted per cell line, and the
ﬁnal karyotype was stated if it was present in N85% of them. For terato-
mas, 2 × 106 iPSCs were injected into the right hind leg of immunocom-
promised NOD/SCID mice. Tumors were excised after 8 weeks, ﬁxed,
embedded in parafﬁn, sectioned and stained with hematoxylin/eosin
(Takahashi et al., 2007).3.6. Mutation analysis
Genomic DNA was isolated from PDX1 P33T and control iPSCs
using standard procedure. PCR ampliﬁcation with a set of primers
ﬂanking the mutation site was performed in those two samples. PCR
products were sequenced using the reverse primer by Sanger sequenc-
ing on an ABI 3130 genetic analyzer (Applied Biosystems). Primers are
as follows: PDX1 forward: GGAGTGTGCAGCAAACTCAG, PDX1 reverse:
ACGCGTGAGCTTTGGTAGAC.
3.7. Immunoﬂuorescence imaging
Cells were ﬁxed with 4% paraformaldehyde for 30 min and then
permeabilized in PBS containing 0.2% Triton X-100. Cells were blocked
with PBS containing 3% BSA, and incubated with primary antibodies
overnight at 4 °C. Then secondary antibodies were incubated for 1 h at
room temperature after washing with PBS. Images were acquired on a
laser scanning microscope. The following antibodies and dilutions
were used: goat anti-OCT3/4 (1:500, Santa Cruz), goat anti-SOX2
(1:500, Santa Cruz), rat anti-SSEA3 (1:50, Invitrogen), mouse anti-
SSEA4 (1:500, Cell signaling) and mouse anti-TRA-1-81 (1:50,
Millipore).
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